Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase II trial to study the effectiveness of hepatic arterial infusion plus chemotherapy in treating patients who have colorectal cancer metastatic to the liver. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations and different ways may kill more tumor cells.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Collaborator: NSABP Foundation Inc
• Treatments: BB 1101; Capecitabine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Floxuridine; Oxaliplatin

Criteria

Inclusion Criteria:

• Histologically confirmed colorectal adenocarcinoma metastatic to the liver

• No extrahepatic metastases

• Prior complete surgical resection of hepatic metastases (at least 1 lesion) within the past 21-56 days

• Negative surgical margins unless surrounding normal liver tissue was ablated during surgery

• Radiofrequency ablation may be used as adjunct to surgical resection but not as primary treatment

• No prior operative ultrasound during resection of hepatic metastases

• Prior complete surgical resection of carcinoma of colon or rectum (must appear completely resectable in case of synchronous lesions)

• Performance status - ECOG 0-1

• Absolute neutrophil count at least 1,200/mm^3

• Platelet count at least 100,000/mm^3

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)

• AST no greater than 2.5 times ULN

• Alkaline phosphatase no greater than 2.5 times ULN

• No pre-existing chronic hepatic disease (chronic active hepatitis or cirrhosis)

• Creatinine no greater than ULN

• Creatinine clearance greater than 60 mL/min

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Adequate oral nutrition (at least 1,500 calories/day)

• Able to withstand major operative procedure

• No dehydration

• No severe anorexia

• No frequent nausea or vomiting

• No prior or concurrent malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of any organ

• No prior or concurrent malignancy associated with more than 10% probability of death from malignant disease within 5 years of diagnosis

• No concurrent immunotherapy

• No concurrent colony-stimulating factors during the first course of study therapy

• No more than 1 prior adjuvant systemic fluorouracil (5-FU) regimen with or without levamisole, leucovorin calcium, or irinotecan

• One prior 5-FU-based regimen as neoadjuvant treatment for rectal cancer is allowed

• No prior hepatic artery infusion therapy with 5-FU or floxuridine

• No prior systemic chemotherapy for metastatic disease

• No other concurrent chemotherapy

• No concurrent radiotherapy

• See Disease Characteristics

• No prior or concurrent sorivudine or brivudine